Skip to content
OpenCapital
Get started

Artiva Biotherapeutics, Inc. ARTV Net interest and investment income (loss)

Other financials

Income statement

See full
Revenue-—
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%—
Net margin-79.3%—

Returns & leverage

See full
Return on equity-67.9%—
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s net interest and investment income (loss).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s net interest and investment income (loss)?
Artiva Biotherapeutics, Inc. (ARTV) reported net interest and investment income (loss) of $912K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s net interest and investment income (loss) changed year-over-year?
Artiva Biotherapeutics, Inc.'s net interest and investment income (loss) decreased by 51.1% year-over-year, from $1.86M to $912K.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s net interest and investment income (loss)?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s net interest and investment income (loss) has grown at a 53.3% compound annual growth rate (CAGR), from $2.54M to $5.96M.